Phibro Animal Health (NASDAQ:PAHC) Shares Gap Down – Time to Sell?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $40.41, but opened at $39.01. Phibro Animal Health shares last traded at $38.1850, with a volume of 68,261 shares changing hands.

Analyst Upgrades and Downgrades

PAHC has been the topic of several research analyst reports. Morgan Stanley set a $34.00 target price on Phibro Animal Health in a research note on Thursday, August 28th. Bank of America boosted their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research report on Friday, August 29th. JPMorgan Chase & Co. upped their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Trading Down 6.9%

The stock’s fifty day simple moving average is $41.48 and its two-hundred day simple moving average is $34.96. The firm has a market cap of $1.52 billion, a PE ratio of 22.69, a PEG ratio of 1.15 and a beta of 0.77. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Insider Activity

In related news, CEO Jack Bendheim sold 38,303 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the transaction, the chief executive officer owned 20,577 shares in the company, valued at $931,932.33. The trade was a 65.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 146,554 shares of company stock valued at $6,338,444. 50.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PAHC. Vanguard Group Inc. grew its holdings in shares of Phibro Animal Health by 0.4% during the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock valued at $32,500,000 after buying an additional 6,784 shares during the last quarter. Acadian Asset Management LLC lifted its position in Phibro Animal Health by 0.5% in the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock valued at $16,713,000 after acquiring an additional 4,144 shares in the last quarter. Geode Capital Management LLC boosted its stake in Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock valued at $14,175,000 after purchasing an additional 7,841 shares during the last quarter. Nuveen LLC bought a new stake in shares of Phibro Animal Health in the 1st quarter worth $10,312,000. Finally, Invesco Ltd. increased its holdings in shares of Phibro Animal Health by 92.3% in the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock worth $8,282,000 after purchasing an additional 186,087 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.